The U.S. Food and Drug Administration (FDA) has approved idelalisib, a PI3K inhibitor, for management relapsed follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, or chronic lymphocytic leukemia [11]. This evidence concerns the gene PIK3CA and B-cell chronic lymphocytic leukemia.